Aclarion Adds First Private Practice Site to CLARITY Trial, Accelerating Enrollment for Nociscan Study

May 11th, 2026 8:51 PM
By: Newsworthy Staff

Aclarion announced the inclusion of Lanman Spinal Neurosurgery in its CLARITY trial, marking the first private practice site, which aims to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain and expedite enrollment.

Aclarion Adds First Private Practice Site to CLARITY Trial, Accelerating Enrollment for Nociscan Study

Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company leveraging biomarkers and augmented intelligence to identify the location of chronic low back pain, announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY trial. Based in Beverly Hills, this private practice is recognized for its expertise in complex spinal procedures and high surgical volume, reflecting growing interest in integrating Nociscan into real-world clinical workflows beyond academic medical centers.

The CLARITY trial (Chronic Low bAck pain Randomized Independent Trial studY) is a prospective, randomized, multi-center study evaluating Nociscan in patients undergoing surgical treatment for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS Back at 12 months compared to baseline. The company anticipates an initial internal data readout and expected public disclosure of early interim results in Q4 2026.

Dr. Todd Lanman, founder of Lanman Spinal Neurosurgery, emphasized the importance of matching the right procedure to the right patient. He noted that Nociscan introduces clarity by using MR Spectroscopy to identify pain-generating discs in ways standard MRI cannot. The CLARITY trial is designed to evaluate how this technology can enhance clinical decision-making by precisely identifying pain-generating discs.

Ryan Bond, Chief Strategy Officer of Aclarion, stated that private practice spine surgeons treat the majority of chronic low back pain patients, and including Lanman Spinal Neurosurgery reflects the demand for precise, data-driven tools in everyday clinical practice. Chronic low back pain affects approximately 266 million people worldwide. Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine, with a 97% surgical success rate when all Nociscan-positive discs are treated.

For more information about CLARITY, visit CLARITY Trial. To find a Nociscan center, view the site map here.

Source Statement

This news article relied primarily on a press release disributed by PRISM Mediawire. You can read the source press release here,

blockchain registration record for the source press release.
;